These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35585597)

  • 21. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues.
    Tamura H; Higa A; Hoshi H; Hiyama G; Takahashi N; Ryufuku M; Morisawa G; Yanagisawa Y; Ito E; Imai JI; Dobashi Y; Katahira K; Soeda S; Watanabe T; Fujimori K; Watanabe S; Takagi M
    Oncol Rep; 2018 Aug; 40(2):635-646. PubMed ID: 29917168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
    Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
    BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Albumin Paclitaxel Compared with 5-Penfluorouracil, Lobaplatin, and Albumin Paclitaxel Combined with 5-Penfluorouracil in the Treatment of Human Gastric Cancer Cell AGS Line Autophagy and Apoptosis.
    Cheng X; Yang F; Wang Y; Nie W; Mahendra Upadhyay A; Zhang M; Wang Q; Yan Z
    Can J Gastroenterol Hepatol; 2022; 2022():6015877. PubMed ID: 35719323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circular RNA circ-PVT1 contributes to paclitaxel resistance of gastric cancer cells through the regulation of ZEB1 expression by sponging miR-124-3p.
    Liu YY; Zhang LY; Du WZ
    Biosci Rep; 2019 Dec; 39(12):. PubMed ID: 31793989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antitumor effect of paclitaxel for gastric cancer is AUC dependent].
    Yamada T; Tanaka N; Furukawa K; Yokoi K; Ishikawa N; Seya T; Horiba K; Kanazawa Y; Shirakawa T; Kudoh H; Koizumi M; Yoshioka M; Shinji S; Katsuta M; Ohaki Y; Tajiri T
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):251-3. PubMed ID: 18281760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer.
    Kang SK; Bae HJ; Kwon WS; Kim TS; Kim KH; Park S; Yu SY; Hwang J; Park J; Chung HC; Rha SY
    Cell Oncol (Dordr); 2021 Dec; 44(6):1387-1403. PubMed ID: 34791636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a Single-Cell Technique to Increase Yield and Use of Gastrointestinal Cancer Organoids for Personalized Medicine Application.
    Gao M; Harper MM; Lin M; Qasem SA; Patel RA; Mardini SH; Gabr MM; Cavnar MJ; Pandalai PK; Kim J
    J Am Coll Surg; 2021 Apr; 232(4):504-514. PubMed ID: 33253861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer.
    Zhu M; Zhang P; Yu S; Tang C; Wang Y; Shen Z; Chen W; Liu T; Cui Y
    J Exp Clin Cancer Res; 2022 Jan; 41(1):14. PubMed ID: 34996504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer.
    Mei Y; Shi M; Zhu Z; Yuan H; Yan C; Li C; Feng T; Yan M; Zhang J; Zhu Z
    Future Oncol; 2022 Jan; 18(2):139-148. PubMed ID: 34877867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma.
    Kim SY; Kim SM; Lim S; Lee JY; Choi SJ; Yang SD; Yun MR; Kim CG; Gu SR; Park C; Park AY; Lim SM; Heo SG; Kim H; Cho BC
    Clin Cancer Res; 2021 Aug; 27(15):4397-4409. PubMed ID: 34083237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Outcome and Problems of Nab-Paclitaxel Therapy for Gastric Cancer in Clinical Practice].
    Doi T; Ishikawa T; Okayama T; Dohi O; Yoshida N; Kamada K; Katada K; Sogame Y; Uchiyama K; Handa O; Takagi T; Yasuda H; Sakagami J; Konishi H; Naito Y; Itoh Y
    Gan To Kagaku Ryoho; 2016 Feb; 43(2):211-4. PubMed ID: 27067684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer.
    Xie BY; Wu AW
    Chin Med J (Engl); 2016 Oct; 129(20):2469-2475. PubMed ID: 27748340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer.
    Kinoshita R; Ishima Y; Chuang VTG; Nakamura H; Fang J; Watanabe H; Shimizu T; Okuhira K; Ishida T; Maeda H; Otagiri M; Maruyama T
    Biomaterials; 2017 Sep; 140():162-169. PubMed ID: 28651144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Graphene oxide (GO)-based nanosheets with combined chemo/photothermal/photodynamic therapy to overcome gastric cancer (GC) paclitaxel resistance by reducing mitochondria-derived adenosine-triphosphate (ATP).
    Guo W; Chen Z; Feng X; Shen G; Huang H; Liang Y; Zhao B; Li G; Hu Y
    J Nanobiotechnology; 2021 May; 19(1):146. PubMed ID: 34011375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.
    Zhang C; Awasthi N; Schwarz MA; Hinz S; Schwarz RE
    PLoS One; 2013; 8(2):e58037. PubMed ID: 23460921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients.
    Chen JH; Chu XP; Zhang JT; Nie Q; Tang WF; Su J; Yan HH; Zheng HP; Chen ZX; Chen X; Song MM; Yi X; Li PS; Guan YF; Li G; Deng CX; Rosell R; Wu YL; Zhong WZ
    Thorac Cancer; 2020 Aug; 11(8):2279-2290. PubMed ID: 32633046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302).
    Tamura S; Taniguchi H; Nishikawa K; Imamura H; Fujita J; Takeno A; Matsuyama J; Kimura Y; Kawada J; Hirao M; Hirota M; Fujitani K; Kurokawa Y; Sakai D; Kawakami H; Shimokawa T; Satoh T
    Int J Clin Oncol; 2020 Dec; 25(12):2035-2043. PubMed ID: 32926227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer.
    Roviello G; Conter FU; Mini E; Generali D; Traversini M; Lavacchi D; Nobili S; Sobhani N
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):669-677. PubMed ID: 31187168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gastric cancer mesenchymal stem cells promote tumor glycolysis and chemoresistance by regulating B7H3 in gastric cancer cells.
    Gao Q; Huang C; Liu T; Yang F; Chen Z; Sun L; Zhao Y; Wang M; Luo L; Zhou C; Zhu W
    J Cell Biochem; 2024 Mar; 125(3):e30521. PubMed ID: 38226525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic efficacy of a paclitaxel-loaded nanofibrillated bacterial cellulose (PTX/NFBC) formulation in a peritoneally disseminated gastric cancer xenograft model.
    Akagi S; Ando H; Fujita K; Shimizu T; Ishima Y; Tajima K; Matsushima T; Kusano T; Ishida T
    Int J Biol Macromol; 2021 Mar; 174():494-501. PubMed ID: 33545180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.